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ABC of palliative care
Principles of palliative care and pain control
Bill O’Neill, Marie Fallon
Principles of palliative care
The World Health Organisation defines palliative care as “the
active total care of patients whose disease is not responsive to
curative treatment. Control of pain, of other symptoms, and of
psychological, social and spiritual problems, is paramount. The
goal of palliative care is achievement of the best quality of life
for patients and their families.”
Palliative care is necessarily multidisciplinary. It is unrealistic
to expect one profession or individual to have the skills to make
the necessary assessment, institute the necessary interventions,
and provide ongoing monitoring.
Development of palliative care
Modern palliative care originated in the development of St
Christopher’s Hospice in London in 1967. Recognising the
unmet needs of dying patients in hospital, Dame Cecily
Saunders established the hospice and, with others, conceived of
a comprehensive approach to dealing with the variety of
symptoms and suffering often experienced by patients with
progressive debilitating disease. Careful observation of the use
and effects of morphine and similar drugs also originated at the
hospice.
Traditionally, hospice care was reserved for those with
incurable cancer. Increasingly, care is provided for other
patients such as those with AIDS and neurological disorders,
including motor neurone disease and multiple sclerosis. When
palliative medicine was accorded specialist standing in the
United Kingdom, in 1987, the agreed definition was “the study
and management of patients with active, progressive,
far›advanced disease, for whom the prognosis is limited and the
focus of care is the quality of life.”
In the past hospices provided only inpatient care, and they
were isolated from mainstream care. Most units now combine
inpatient and home care services, and many independent home
care teams also exist, working closely with general practitioners
and other workers in primary care. Similarly, many acute
hospital and teaching centres now have consultative, hospital
based teams.
While hospices will always be needed to care for some
patients, the philosophy of care and knowledge gained must be
integrated into other specialties. After appropriate assessment,
the various methods of symptom control described in this series
can be applied at any stage of many illnesses. Symptoms can be
relieved while awaiting a response to curative treatment.
Components of palliative care
The essential components of palliative care are effective control
of symptoms and effective communication with patients, their
families, and others involved in their care. Rehabilitation, with
the aim of maximising independence, is also essential to good
care. As a disease progresses, continuity of care becomes
increasingly important—coordination between services is
required, and information must be transferred promptly and
efficiently between professionals in the community, in hospitals,
and in hospices.
Role of specialists—Most palliative care is provided by general
practitioners and by doctors in specialties other than palliative
medicine. Specialists in palliative medicine aim to provide care
Palliative care
x Affirms life and regards dying as a normal process
x Neither hastens nor postpones death
x Provides relief from pain and other distressing symptoms
x Integrates the psychological and spiritual aspects of care
x Offers a support system to help patients live as actively as possible
until death
x Offers a support system to help patients’ families cope during the
patient’s illness and in their own bereavement
Palliative care services in United Kingdom
and Republic of Ireland*
Service
Inpatient units
Beds
Day care centres
Home care teams
Hospital support teams
Hospital support nurses
No of units
223
3253
234
408
139
176
*Data from St Christopher’s Hospice Information Service
Essential components of palliative care
x Symptom control
x Effective communication
x Rehabilitation
x Continuity of care
x Terminal care
x Support in bereavement
x Education
x Research
Dame Cecily Saunders, founder of St Christopher’s
Hospice. (Reproduced with permission)
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for those who need inpatient care or with difficult symptoms,
undergraduate and postgraduate education, and research.
Education is the key to palliative care for all, and, without
research, advances in the science of symptom control and
quality of care will stagnate.
Funding—The funding of palliative care services differs from
that of the rest of the heath service. Only about a fifth of
inpatient units in the United Kingdom are funded exclusively
by the NHS. Most are funded by the voluntary sector with some
financial support from the health service. Although there is a
growing partnership between the government and the
voluntary hospice sector, voluntary hospices still rely greatly on
the goodwill and fundraising initiatives of local communities.
Allocating resources to palliative care
Traditionally, in cancer care resources were allocated to
palliative care only after aggressive attempts to halt the cancer
had failed. Palliative care is an integral part of the care of all
patients: it does not equate with care at the end of life.
Worldwide, most cancer patients have no hope of cure, and
this is particularly true of developing countries, many of which
have no screening services for cancer, very limited access to
diagnostic facilities, and few specialist cancer doctors. Because
of this, the WHO has suggested that, in the developing world, a
greater proportion of resources for cancer care should be
allocated to palliative care.
While there are serious shortages of essential drugs for pain
control, political and cultural attitudes against the use of opioids
are major factors in poor control of symptoms worldwide. This
highlights the need for national, economic, and political policies
on cancer and palliative care.
Principles of managing cancer pain
For most patients, physical pain is only one of several
symptoms. Relief of pain should therefore be seen as part of a
comprehensive pattern of care encompassing the physical,
psychological, social, and spiritual aspects of suffering. Physical
aspects of pain cannot be treated in isolation from other
aspects, nor can patients’ anxieties be effectively addressed when
patients are suffering physically. The various components must
be addressed simultaneously.
The first principle of managing cancer pain is an adequate
and full assessment of the cause of the pain, bearing in mind
that most patients have more than one pain and different pains
have different causes. A comprehensive knowledge of the
underlying pathophysiology of pain is essential for effective
management. With effective assessment and a systematic
approach to the choice of analgesics, over 80% of cancer pain
can be controlled with the use of inexpensive drugs that can be
self administered by mouth at regular intervals. Consideration
must always be given to treating the underlying cause of the
pain by means of surgery, radiotherapy, chemotherapy, or other
appropriate measures.
Analgesic drugs
Analgesic drugs form the mainstay of managing cancer pain.
The choice of drug should be based on the severity of the pain,
not the stage of disease. Drugs should be administered in
standard doses at regular intervals in a stepwise fashion. If a
non›opioid or, in turn, a weak opioid is not sufficient, a strong
opioid is used. Either a weak or a strong opioid should be used,
not both.
Adjuvant analgesic drugs may be usefully added at any
stage. An adjuvant analgesic is a drug whose primary indication
is other than pain but which has an analgesic effect in some
Some of the national charities—in
particular, Macmillan Cancer Relief,
Marie Curie Cancer Care, and the Sue
Ryder Foundation—are major providers
of palliative care, while others such as
Help the Hospices and the Scottish
Partnership Agency do much to promote
and support the work of hospices
Analgesic drugs commonly recommended for cancer pain
Mild pain
x Aspirin 600 mg every 4 hours
x Paracetamol 1 g every 4 hours
Moderate pain
x Codeine 60 mg (plus non›opioid drug) every 4 hours
x Dextropropoxyphene 65 mg (plus non›opioid drug) every 4 hours
Severe pain
x Morphine 5›10 mg (starting dose) every 4 hours
Anticancer treatment
Traditional allocation of resources
Cancer pain
relief and
palliative care
Anticancer treatment
Current allocation of resources in developed countries
Cancer pain relief and palliative care
Anticancer treatment
Proposed allocation of resources in developing countries
At time of
diagnosis
Death
Cancer pain relief and palliative care
Models of allocation of resources for care of cancer patients
Physical pain
  Other symptoms
  Adverse effects of treatment
Total
pain
Anxiety
  Fear of hospital or nursing home
  Fear of pain
  Worry about family and finances
  Fear of death
  Spiritual unrest, uncertainty about future
Depression
  Loss of social position
  Loss of job prestige and income
  Loss of role in family
  Insomnia and chronic fatigue
  Sense of helplessness
  Disfigurement
Anger
  Bureaucratic bungling
  Delays in diagnosis
  Unavailable physicians
  Uncommunicative physicians
  Failure of therapy
  Friends who do not visit
Factors affecting patients’ perception of pain
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painful conditions. Examples are corticosteroids, non›steroidal
anti›inflammatory drugs, tricyclic antidepressants,
anticonvulsants, and some antiarrythmic drugs.
When a non›opioid drug is used together with a weak
opioid, many patients find combination formulations more
convenient to use. Care must be taken with the dose of each
drug in the formulation; some combinations of codeine or
dihydrocodeine with aspirin or paracetamol (including
co›codamol and co›dydramol) contain subtherapeutic doses of
the weak opioid. If these are used and are not effective, more
appropriate doses of codeine or dihydrocodeine should be used
before moving to strong opioids. The decision to use a strong
opioid should be based on severity of pain and not on
prognosis.
Strong opioid analgesics
Morphine is the most commonly used strong opioid analgesic.
When possible, it should be given by mouth, the dose tailored
to each patient, and doses repeated at regular intervals so that
the pain is prevented from returning. There is no arbitrary
upper limit, but negative attitudes to using morphine still exist;
the skilled use of morphine will confer benefit rather than
harm, but many patients express fears, which should be
discussed.
Dose titration—A quick release formulation of morphine
(either elixir or tablet), with a rapid onset and short duration of
action, is preferred for dose titration. The simplest method is to
prescribe a regular, four hourly dose but allow extra doses of
the same size for “breakthrough pain” as often as necessary.
After 24 or 48 hours, the daily requirements may be reassessed
and the regular dose adjusted as necessary. This process is
continued until pain relief is satisfactory. By this method, the
many factors that contribute to the variability in dose are taken
into account. These include the severity of the pain, the type of
pain, the affective component of pain, and variation in
pharmacokinetic parameters. The regular dose used may range
from 5›10 mg to 2500 mg or more (or the equivalent in
controlled release tablets). The dose is titrated against effect, and
very few patients need high doses—most require less than
200 mg a day.
Maintenance dose—Patients with advancing disease and
increasing pain may require continual adjustment of dose. For
many patients, however, there is a period of stability during
which the dose required remains unchanged or needs only
small adjustments, and this may last for weeks or months or
sometimes longer. Once pain is relieved, maintenance will be
with a controlled release morphine preparation. Controlled
release morphine is available as a once daily preparation that
remains effective for 24 hours or a twice daily preparation with
effects that last 12 hours.
Alternative routes of administration
The rectal bioavailability of morphine is similar to its oral
bioavailability, and it is widely available in suppository form.
The rectal route may be appropriate in patients unable to take
drugs by mouth, and the same dose as that taken orally should
be given four hourly.
For many patients, however, it may be more convenient to
convert directly to a subcutaneous infusion of opioid via an
infusion device such as a portable, pocket sized, syringe driver.
This simple technique allows continuous infusion of opioid
analgesics in patients unable to take drugs by mouth. The
relative potency of opioids is increased when they are given
parenterally: the oral dose of morphine should be divided by
two to get the equianalgesic dose of subcutaneous morphine
and by three when converting to subcutaneous diamorphine.
Opioid alternatives to morphine
Hydromorphone—Has recently become available in Britain. Titration is
usually with hydromorphone quick release capsules; when pain is
controlled, patients may convert to controlled release
preparation. As it is about seven times as potent as morphine,
care is needed with patients with no prior exposure to opioids
Fentanyl—Self adhesive patches provide transcutaneous delivery of
strong opioid. The patch is changed once every 72 hours. It is used
with quick release morphine for breakthrough pain. It is suitable
only for patients whose pain is stable because of the time required
to titrate the dose upwards. It takes up to 24›48 hours before peak
plasma concentrations are achieved
Diamorphine, available only in Britain and Canada, is a semisynthetic
derivative and a prodrug of morphine. Use of oral diamorphine is
an inefficient way of delivering morphine to the body, but, for
parenteral administration, its greater solubility confers an advantage
over morphine
Buprenorphine has the advantage of sublingual administration, but it is
not recommended except for patients requiring only small doses of
opioid
Dextromoramide and pethidine are short acting opioids and not
appropriate for the management of chronic pain
Non-opioid
–  Adjuvant
Opioid for mild to
moderate pain
+ Non-opioid
–  Adjuvant
Opioid for moderate
to severe pain
+ Non-opioid
–  Adjuvant
Pain persisting
or increasing
Pain
Pain persisting
or increasing
Freedom from
cancer pain
1
2
3
WHO’s three step ladder to use of analgesic drugs
Portable syringe driver for automatic drug infusion
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Rarely, patients may require intravenous administration, and
this route may be particularly appropriate for those with an
indwelling central line, particularly children.
The indications for administration of strong opioids by
intrathecal or epidural routes remain somewhat controversial.
There is agreement that patients with pain that is sensitive to
opioids who experience intolerable adverse effects with systemic
administration may be able to tolerate epidural or intrathecal
administration, since much smaller doses of opioid are required
to get the same analgesic effect. The more widespread use of
these routes is, in general, not justified.
Tolerance and addiction
Tolerance to opioids is rarely seen in the clinical practice of
managing cancer pain. Requirements for increasing doses of
morphine can usually be explained by progressive disease
rather than pharmacological tolerance. Psychological
dependence or addiction is not a problem except in patients
with pre›existing addiction. If alternative methods of pain
control are used (such as nerve blocks) it is usually possible to
reduce the dose of the analgesic or even withdraw it without
adverse psychological effects.
Opioid toxicity
There is wide variation, both between individuals and over time,
in the dose of opioid that is toxic. The ability to tolerate a
particular dose depends on the degree of responsiveness of the
pain to opioid, prior exposure to opioids, rate of titration of the
dose, concomitant medication, and renal function. Toxicity can
be a frightening and life threatening experience, but it is usually
reversible.
Opioid toxicity may present as subtle agitation, seeing
shadows at the periphery of the visual field, vivid dreams, visual
and auditory hallucinations, confusion, and myoclonic jerks.
Agitated confusion may be interpreted as uncontrolled pain
and further opioids given. A vicious cycle then follows, in which
the patient is given sedation and may become dehydrated,
resulting in the accumulation of opioid metabolites and further
toxicity.
Management includes reducing the dose of opioid, ensuring
adequate hydration, and treating the agitation with haloperidol
(1.5›3 mg orally or subcutaneously, repeated hourly as needed).
Subsequent increases in opioid dose may be tolerated.
Opioid responsiveness
Some pains do not respond well to opioids. Although no pain
can be assessed as unresponsive to opioids before a careful
therapeutic trial of the drug, some pains are more commonly
poorly responsive to opioids. These include bone, neuropathic,
and visceral pain. Adjuvant drugs, radiotherapy, and anaesthetic
block techniques may be helpful in such cases. Radiotherapy
provides effective relief of pain from bone metastases—a single
fraction is often sufficient, thus avoiding frequent trips to
hospital. Problems with difficult pain will be addressed in the
next article in this series.
Common adverse effects of opioids
Sedation—Some sedation is common at the start of treatment, but in
most patients it resolves within a few days
Nausea and vomiting—Nausea is common in patients taking oral
morphine, vomiting rather less so. These are initial side effects and
usually resolve over a few days, but they can easily be controlled—
metoclopramide (10 mg every eight hours) or haloperidol (1.5 mg
at night or twice daily) is effective for most patients
Constipation develops in almost all patients and should be treated
prophylactically with laxatives
Dry mouth is often the most troublesome adverse effect for patients.
Patients should be advised on simple measures to combat this, such
as frequent sips of cool drinks or sucking boiled sweets, ice cubes, or
frozen segments of fruit such as pineapple or melon
Common adjuvant analgesics for cancer pain
Drug Indications
Non›steroidal
anti›inflammatory drugs
Bone pain
Soft tissue infiltration
Hepatomegaly
Corticosteroids Raised intracranial pressure
Soft tissue infiltration
Nerve compression
Antidepressants
Anticonvulsants
Antiarrythmics
Nerve compression or infiltration
Paraneoplastic neuropathies
Bisphosphonates Bone pain
The drawings of resource allocation for cancer care, the WHO three step
analgesic ladder, and factors affecting perception of pain are redrawn, with
permission, from the WHO’s Cancer pain relief and palliative care (technical
report series 804). Geneva: WHO, 1990.
Bill O’Neill is science and research adviser, British Medical
Association, BMA House, London. Marie Fallon is Marie Curie senior
lecturer in palliative medicine, Beatson Oncology Centre, Western
Infirmary, Glasgow.
The ABC of palliative care is edited by Marie Fallon and Bill O’Neill
and will be published as a book in June 1998.
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